BMSD : 10.65048
BMSD : 10.65048
https://doi.org/10.65048/ijbmr
Search
About Us
Authors
Reviewers
Editorial Board
Contact Us

International Journal of Biological and Medical Research (IJBMR)

Case Study
Year : 2026  |  Volume : 17  |  Issue : 4  |  Page : 8896-8899 Full Version
Endobronchial metastasis from primary chest wall leiomyosarcoma: a rare pattern of recurrence
Int J Biol Med Res. 2026; 17(4): 8896-8899  |  DOI: 10.65048/ijbmr.2026.17.4.8896.1110
Muhammad Ahmad¹, Muhammad Adil Jehangir Khan¹, Dr. Syed Murtaza Hassan Kazmi², Dr. Zafar Ali³, Dr. Asif Masood⁴
¹ Medical Student, Shifa College of Medicine, Islamabad, Pakistan.
² Chief of Pulmonology, Shifa International Hospital, Islamabad, Pakistan
³ Head of Department of Histopathology, Shifa International Hospital, Lahore, Pakistan
⁴ Department of Radiation Oncology, Shifa International Hospital, Islamabad, Pakistan
Correspondence Address :
Muhammad Ahmad,
Final Year MBBS Student,
Shifa College of Medicine,
Islamabad, Pakistan E-mail: amdz.khan10@gmail.com
Received: May 14, 2026 Accepted: July 26, 2026 Published: October 3, 2026

Abstract
Leiomyosarcomas are a type of soft tissue tumor. They have a low incidence and can arise in any part of the body, commonly arising in the intrabdominal viscera. They have unique metastatic characteristics. Here we discuss the case of a 54-year-old hypertensive man who presented initially with a right sided anterior chest wall mass. Investigations confirmed it to be a chest leiomyosarcoma. He was treated with surgical resection and reconstruction along with adjuvant radiotherapy. Ten months later, he presented again with complaints of large volume hemoptysis. Workup showed that the patient had developed a metastatic lesion in the right main bronchus. Endobronchial biopsy and EBUS-TBNA confirmed metastatic leiomyosarcoma. From our literature review and knowledge, we conclude that this is the first reported case of a leiomyosarcoma metastasizing to the endobronchial region. The discussion explores the novelty of this metastatic pathway, diagnostic challenges, and the importance of bronchoscopy and multidisciplinary care in guiding surveillance and palliation.
Keywords
Cancer, Chest leiomyosarcoma, Endobronchial, Metastasis, Oncology, Pulmonology

Introduction

Leiomyosarcomas, are tumors of the smooth muscle cells, which come under the umbrella term of sarcomas (soft tissue tumors) [1]. They roughly make up about 10-20% of all the sarcomas [1]. The most common site is the uterus; however, they can arise in essentially any part of the body, including retroperitoneally (IVC etc.), extremities and the skin as well [1]. About 90% of them usually arise in intra-abdominal organs or the venous structures that are present retroperitoneally [2]. Leiomyosarcomas that are outside the abdomen make up around 10% of the total cases and these arise from the trunk, extremities and head and neck region [2]. Primary chest leiomyosarcomas are exceedingly rare and have been reported in only with 1-4% of people with sarcomas [3]. Leiomyosarcomas are characterized as tumors with a high risk of distant metastasis, the percentage of 10-year metastasis for these kinds of tumors is between 31-71% and this in turn depends on the site of origin [1]. In terms of reported cases of metastasis, there are several studies that talk about metastasis of uterine leiomyosarcoma [4,5]. However, literature does not properly define the metastatic features of leiomyosarcomas that arise from the trunk and extremities [6].

Here we present the case of a 54-year-old man who was diagnosed with a primary leiomyosarcoma of the chest for which he underwent surgical intervention. Ten months later, he presented with complaints of large volume hemoptysis. Workup was initiated and he was diagnosed with a metastatic endobronchial recurrence. 

CASE REPORT:

A 54-year-old man, known hypertensive, presented in July 2024 with a 4-month history of a gradually enlarging, mildly painful swelling in the right parasternal region. There were no other complaints. No respiratory or systemic symptoms. Upon examination, there was a hard, fixed, non-tender anterior chest wall mass. Contrast-enhanced CT showed a lobulated soft tissue lesion involving the right anterior chest wall, uplifting the pectoralis muscle, eroding the sternum and adjacent costal cartilages, and abutting the pericardium without distant disease. Bone scan was negative. In late July 2024, he underwent wide resection with removal of involved sternum and ribs, followed by mesh and bone graft reconstruction. Frozen sections confirmed negative margins. Histopathology revealed a moderately differentiated (FNCLCC grade 2) leiomyosarcoma, 4.5 × 4.0 × 2.0 cm, with 14 mitoses/10 HPF, <50% necrosis, and negative margins (closest 2 mm). Immunohistochemistry was positive for smooth muscle actin and caldesmon, and negative for cytokeratin, desmin, S-100, and calretinin. Stage: pT1Nx. He completed adjuvant intensity-modulated radiotherapy (60 Gy in 30 fractions) by October 2024. Surveillance CT in January 2025 showed only post-treatment changes. In May 2025, he developed large-volume hemoptysis. CT demonstrated multiple enlarged confluent necrotic appearing right hilar and paratracheal nodal masses protruding into and occluding the right upper lobe and mainstem bronchus at the level of bronchus intermedius, this suggested metastatic disease. It is shown in figure 1 [A, B, C]. A Bronchoscopy was planned.  Bronchoscopy revealed a lobulated mass nearly occluding the right main bronchus distal to the carina. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was performed. It revealed a large endobronchial tumor arising from the right upper lobe which obstructed the right main bronchus. Bronchoscopy was also done, it is shown in figure 2. Biopsy was taken from the right main bronchus and sent for histopathology, microbiology and immunohistochemistry. Histopathology and immunohistochemistry, shown in figure 3, was consistent with metastatic leiomyosarcoma, identical to the primary tumor.

Figure 1 (A) The image shows a right paratracheal/precarinal soft tissue mass that is likely metastatic in nature. (B) The image shows a mass extending towards the carina/proximal right main bronchus and obstructing the lumen of the right main bronchus. (C) The image shows a mass within the right main bronchus and it is occluding the lumen of the right bronchus, left main bronchus is patent.

Figure 2 This image shows the right main bronchus that is being obstructed by the metastatic lesion, this is the view from the bronchoscope.

Figure 3 (A) Hematoxylin and eosin–stained section demonstrates a malignant spindle cell neoplasm composed of intersecting fascicles of elongated cells with eosinophilic cytoplasm and blunt-ended (“cigar-shaped”) nuclei, consistent with leiomyosarcoma (x200). (B) Immunohistochemistry for h-caldesmon shows strong cytoplasmic positivity in tumor cells, supporting smooth muscle differentiation (x200)

Microbiological cultures were negative. Due to the tumor blocking the bronchus, he got postobstructive pneumonia, it was treated with intravenous meropenem, vancomycin, corticosteroids, and supportive care. Given advanced unresectable disease, multidisciplinary consensus favored palliative management. The clinical course of the patient is summarized in table 1.

TABLE 1

Date / Interval

Clinical Event

Key Findings / Interventions

Outcome

July 2024

Initial presentation

4-month history of enlarging right parasternal chest wall mass; exam: hard, fixed, non-tender lesion

Work-up initiated

July 2024

Diagnostic imaging

CT: lobulated anterior chest wall lesion eroding sternum & costal cartilages; abutting pericardium; bone scan negative

No distant disease

Late July 2024

Surgery

Wide resection of sternum & ribs with mesh/bone graft reconstruction; margins negative

Uneventful recovery

Post-op July 2024

Histopathology

Moderately differentiated leiomyosarcoma (FNCLCC grade 2, 4.5 × 4.0 × 2.0 cm, 14 mitoses/10 HPF, <50% necrosis, IHC SMA+, caldesmon+); stage pT1Nx

Diagnosis confirmed

Aug–Oct 2024

Adjuvant therapy

Intensity-modulated radiotherapy (60 Gy in 30 fractions)

Completed

Jan 2025

Surveillance

CT chest: only post-treatment changes

No recurrence

May 2025

Recurrence presentation

Hemoptysis; bronchoscopy: lobulated mass occluding right main bronchus

Suspicion of recurrence

May 2025

Imaging

CT: necrotic right hilar & paratracheal nodal masses, airway obstruction, hepatic lesions

Metastatic disease suspected

May 2025

Tissue confirmation

Endobronchial biopsy: metastatic leiomyosarcoma; EBUS-TBNA: Right Main Bronchus obstruction arising from right upper lobe.

Diagnosis of metastatic recurrence

May 2025 onward

Management

IV meropenem, vancomycin, corticosteroids; multidisciplinary tumor board discussion

Palliative care initiated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

TABLE 1: This table shows the entire clinical course of the patient.

Discussion

Leiomyosarcomas, a rare type of sarcomas that can arise in essentially any part of the body. They have a high risk of distant metastasis. Endobronchial metastasis (EBM) from them is an even rarer entity with no cases defined in literature. Endobronchial metastasis (EMB) is defined a non-pulmonary lesion visualized by bronchoscopy, in the proximal central bronchus or subsegmental bronchi and histologically parallel to the primary tumor [4]. A lot of study has been done in order to understand how these malignant lesions develop. Four developmental modes for endobronchial metastasis have been put forward, type 1, direct metastasis, type 2 includes those that occur through bronchial invasion by a lesion from the parenchyma, type 3, metastasis from lymph nodes and 4, peripheral lesions extending into the bronchus [4]. In our case, the disease most likely stemmed from a metastatic lesion from a lymph node as suggested by the EBUS-TBNA. The incidence of EBM ranges from 2-28% [7]. One of the reasons contributing to this low incidence is that bronchoscopy is not a routine investigation for patients with pulmonary metastasis, this may be the reason for it being underreported [7]. Being a rare entity itself, combined with the lack of routine specialized investigations, one can understand the reason of it being statically underreported.  A study that aimed to understand the clinicopathological course and development of endobronchial metastasis showed that, EBM could be due to a variety of primary tumors, most commonly from breast, colorectal and renal carcinomas [5]. However, our patient had no such primary or metastatic lesions and this finding makes the case even more unique. No study states any genetic, vascular, lymphatic or any other channel that could have led to the development of this lesion. There were zero patients who had EMB through chest wall malignancies. Another study of 204 patients had consistent findings [8]. Furthermore, a rather interesting point to be noted in our patient is the short time in which he developed relapse, which was about 11 months. On the other hand, Studies report that endobronchial metastasis takes a long time to develop with the median being 10 years [5]. A study showed that the occurrence of endobronchial lesions was equal on right and left sides [8].  Our patient had a right sided lesion. Venturing further into understanding how a patient would present in-case of endobronchial metastasis, literature showed that the most common clinical manifestations include hemoptysis, cough and dyspnea. Our patient presented with similar complaints particularly of hemoptysis. Since these lesions can be confused with other pulmonary or bronchogenic malignancies as it a rare finding, it is necessary to use different modalities to correctly identify it [9]. The different modalities include biopsy (via bronchoscopy or surgery), CT, X-rays, EBUS-TBNA and bronchoalveolar lavage [9,10]. Biopsy is the choice of investigation however biopsy via bronchoscopy has a high false positive rate and surgical biopsies are invasive and expensive. While CT provides valuable information, it cannot demonstrate intraluminal lesion [9]. In this patient, CT identified confluent masses that produced right sided obstruction. The presence of an effusion, lymphadenopathy (hilar and mediastinal) and atelectasis suggest the presence of a lesion in the endobronchial region [10].  Due to the discrepancy in diagnosis, definitive identification requires microscopic examination of EBM and the primary tumor and their comparison to see the identical histological features [9]. Regardless of the discrepancies noted in literature, EBUS biopsy helped us diagnose the lesion. It is an extremely valuable tool that does play a major role in the diagnosis of such metastatic lesions and should be considered in patients with suspected mets to the endobronchial region. Immunohistochemical staining should also be performed as it helps determine the primary tumor site. It helps identify similar morphological properties and look for similar immunohistochemical expression patterns. Our patient had tumor cells that were positive for both Smooth-Muscle Actin (SMA) and H-Caldesmon, his primary leiomyosarcoma demonstrated a similar immunoreactive profile.

 For management of such lesions, personalization of therapy is required on the basis of the patient's biological status, number of lesions, size and site of primary tumor, and other metastatic sites. There are two approaches to management, palliative and treatment. Intrabronchial stenting, laser evaporation and brachytherapy are palliative. Surgery, chemo and radiotherapy make up the treatment approach [7]. Surgical procedures include radical surgery for early endobronchial mets with a single lesion whereas pneumonectomy and lobectomy are more favorable in cases of confined metastatic lesions [10]. In cases where surgery is not possible, chemotherapy and radiotherapy are the mainstay of management [9]. Our patient was managed by a multidisciplinary team which comprised of trained specialists from the department of Radiology, Pulmonology, Radiation Oncology and Palliative Care team.

Conclusions

Endobronchial metastasis from a leiomyosarcoma is an extremely rare phenomenon. It should be kept in mind as an important differential in patients who have been diagnosed with an extrapulmonary malignancy and are having symptoms like cough, hemoptysis, dyspnea etc. A holistic approach should be taken in order to diagnose and manage this condition. Treatment has to be tailored according to the stage of the disease and the overall health of the patient.

Acknowledgements

Ethical Approval

Ethical Approval was taken from the Institutional Review Board (IRB) of our Institution.

Muhammad Ahmad and Muhammad Adil Jehangir wrote the 1st draft and prepared the final manuscript.  Dr. Murtaza Hassan Kazmi, Dr. Asif Masood and Dr. Zafar Ali helped with grammar correction, proof-reading and details of patient management. Dr. Murtaza Hassan Kazmi helped with interpretation of EBUS and CT. Dr. Zafar Ali prepared and helped interpret immunohistochemistry and histopathology slides.  

Funding:

All authors certify that they have no affiliation with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.




Conflicts of Interest:

Authors don't have any conflict of Interest.


References

[1] Denu RA, Dann AM, Keung EZ, Nakazawa MS, Nassif Haddad EF. The future of targeted therapy for leiomyosarcoma. Cancers (Basel). 2024; 16:938.
[2] Devaud N, Vornicova O, Abdul Razak AR, Khalili K, Demicco EG, Mitric C, et al. Leiomyosarcoma: Current clinical management and future horizons. Surg Oncol Clin N Am. 2022; 31:527–546.
[3] Matsumoto J, Sugiura H, Morikawa T, Kaji M, Kondo S, Okushiba S, et al. A case of primary leiomyosarcoma of the chest wall successfully resected under the video-assisted thoracoscopic approach. Ann Thorac Cardiovasc Surg. 2001; 7:368–370.
[4] Ghosh S, Kundu S, Pal A, Paul S. Rare endobronchial metastasis from uterine leiomyosarcoma. Lung India. 2015; 32:155–157.
[5] Ono M, Kobayashi S, Hanagama M, Ishida M, Sato H, Okutomo K, et al. A case of metastatic endobronchial tumor from uterine leiomyosarcoma. Respir Med Case Rep. 2022; 40:101747.
[6] Tigchelaar SS, Frey C, Sivaraj D, Segovia NA, Mohler DG, Steffner RJ, et al. Metastatic pattern of truncal and extremity leiomyosarcoma: Retrospective analysis of predictors, outcomes, and detection. J Pers Med. 2022; 12:345.
[7] Kadamkulam Syriac A, Bhaskarla AV, Elrifai M, Alraiyes AH. Endobronchial metastasis as an uncommon pattern of metastatic dissemination from small cell osteosarcoma. BMJ Case Rep. 2019; 12:e229779.
[8] Sørensen JB. Endobronchial metastases from extrapulmonary solid tumors. Acta Oncol. 2004; 43:73–79.
[9] Abdul Rahman S-A, Abdul Rahman A, Rajab S, Mansour S, Mansour M, Salloum E, et al. Endobronchial metastasis secondary to occulting renal cell carcinoma: Literature review and a rare case report. BMC Pulm Med. 2023; 23:28.
[10] Zhang G-L, Chen S, Li J-D, Wang C-G. Endobronchial metastasis of renal carcinoma: A case report and review of previous literature. Front Surg. 2021; 8:658749.


IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications